After a long wait for the vaccine of the coronavirus, pharmaceutical companies in India are all set to launch the vaccine in the next few months. Having passed the pre-clinical trials level I and II, now heading on to the clinical trials, which is good news to hear because once the track begins it would take around a month for further analysis and then the release of the vaccine, being awaited for so long.
Looking at the global aspect, 26 vaccine candidates are being developed, as per WHO. As we talk of today, Russia even released one of the corona vaccines which was the need of the hour to reduce the impact of the pandemic. Let us now take a view of our country’s stand, while working in the field.
THE INDIAN ASPECT
The very first vaccine being under work right now is the Bharat biotech vaccine and the DNA vaccine of Zydus Cadila, that have completed phase1 and phase2 clinical trials and are currently being passed for the next clinical phase. ICMR currently is working on three vaccines, under various pre-clinical examination.
The next in the list is the vaccine produced by the SII (Serum Institute of India) in collaboration with Oxford Vaccine, which has been approved for phase 2 and 3 clinical trials, further which would begin by the end of the week.
The next vaccine being under work right now is by the Immunology and Vaccine Research Center, Bangalore in collaboration with Emory Vaccine Center of Atlanta University.
Talking in-depth about SII, it has now entered into a partnership with international vaccine alliance Gavi & Melinda Gates Foundation, to increase the production of higher dosages. Plus point of SII made vaccine would be the cost that would help it being available to not only the high-class, but also to the marginal.
SII is currently aiming to produce world’s largest vaccine by volume, using a strategic investment fund; aiming the vaccine to be available at Rs. 225/ dose. Bill and Melinda Gates Foundation, currently working on the vaccine procurement is aiming to release the vaccine by the next two months.
The oxford vaccine named “ChAdOx1 nCoV-2” was developed three months ago, using a weakened strain of adenovirus infectious to chimpanzees. On clinical tests, it was found that six monkeys infected with SARS- CoV-2 showed a significant repair in the lungs. The pre-clinical trial is awaited and is assumed to begin by the end of the month.
JOHNSON & JOHNSON VACCINE
While talking about the Johnson and Johnson vaccine. It has been approved for trial in phase 1 clinical study to be held in September. The results are being awaited to be positive. If approved, the vaccine would be available by the end of the year.
THE WAIT IS FINALLY GOING TO END!
The next vaccine under manufacture is that of Bharat Biotech International Ltd., naming the vaccine as Bacille Calmette-Guerin vaccine, currently being tested on 6000 high-risk individuals, aiming to boost their immunity against COVID-19. BBIL is currently allocated Rs 100 crore, from PM care, so as to complete the research, saving mankind.
If everything goes right, we will soon get rid of corona virus that has been conquering us in several ways.